deltatrials
Completed PHASE2 NCT00041067

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Breast Cancer
Interventions docetaxel filgrastim trastuzumab vinorelbine
Updated 7 times since 2017 Last updated: May 20, 2013 Started: Sep 30, 2002 Primary completion: Jan 31, 2008 Completion: Jan 31, 2012

This PHASE2 trial investigates Breast Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — May 2023 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Alton, United States, American Fork, United States, Anderson, United States, Ann Arbor, United States, Auburn, United States, Bay City, United States, Bellingham, United States, Billings, United States, Boise, United States and 81 more location s